The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease

Miki, Kazunori; Moore, David; Butler, Ross N.; Southcott, Emma; Couper, Richard; Davidson, Geoffrey P.

doi:10.1016/s0022-3476(98)70145-3

Cited by 65 publications

(49 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intestinal permeability (IP) tends to be higher in humans with Crohn's disease (Püspök et al, 1998), coeliacal sprue , or ulcerative colitis (Miki et al, 1998). IP may also be enhanced with some chemical or physical stimuli, long-time fasting, exercise (Pals et al, 1997), following the administration of non-steroid antiinflammatory drugs (Suenaert et al, 2000;Gotteland et al, 2001) or alcohol (Napolitano et al, 1995).…”

Section: Introductionmentioning

confidence: 99%

Assessment of intestinal permeability in preruminant calves by lactulose/mannitol test

Klein¹,

Moravcová²,

Kleinová³

et al. 2007

J. Anim. Feed Sci.

View full text Add to dashboard Cite

The aim of this study was to utilize the lactulose/mannitol test for assessment of intestinal permeability (IP) in preruminant calves. IP was increased experimentally by administration of Indomethacin. Both sugar markers were determined simultaneously as silyl-derivates in 5 h urinary production using the gas liquid chromatography technique. The index of IP was determined as the ratio between urinary recovery (%) of 10 g lactulose to 5 g D-mannitol. The IP index in control calves was 0.242±0.048. Doses of 20 and 60 mg Indomethacin did not significantly affect IP, but the IP index was significantly enhanced in calves receiving 120 mg of drug (0.541±0.091; P<0.01). Results of this study show that ratio of lactulose to D-mannitol in urine reflected the treatment by the highest dose of Indomethacin and that the test may be used for determination of IP in preruminant calves.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of intestinal permeability in preruminant calves by lactulose/mannitol test

Klein¹,

Moravcová²,

Kleinová³

et al. 2007

J. Anim. Feed Sci.

View full text Add to dashboard Cite

show abstract

“…Increased intestinal permeability has been reported in human patients with Crohn's disease, and interestingly, even in asymptomatic relatives of patients with Crohn's disease; this suggests the presence of a genetic predisposition [8]. Furthermore, several studies have indicated that the mucosal permeability test could be used as a marker for disease activity and relapse in patients with IBD [3,9,13].…”

mentioning

confidence: 97%

Measurement of Intestinal Mucosal Permeability in Dogs with Lymphocytic-Plasmacytic Enteritis

Kobayashi

Ohno

Uetsuka

et al. 2007

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Lymphocytic-plasmacytic enteritis (LPE) is a type of canine inflammatory bowel disease (IBD). One of its most probable causes is a defect in the mucosal permeability barrier. In the present study, intestinal permeability in LPE dogs was examinated to evaluate its clinical value. Twenty-nine dogs with LPE diagnosed by clinical and histological examinations were included in this study. Intestinal permeability was evaluated by measuring the ratio of the concentrations of two sugars (lactulose (L) and rhamnose (R)) with different molecular weights in urine samples after oral administration of a solution containing them. Biopsy specimens of duodenum were evaluated according to histological criteria. The urinary L:R ratio in the 29 LPE dogs (1.68 ± 1.17, mean ± SD) was significantly higher than that in the 10 healthy control dogs (0.75 ± 0.38, P<0.01). In the LPE dogs, a weak correlation was observed between the histopathological grading score of the duodenum and the urinary L:R ratio (r=0.408, P<0.05). The urinary L:R ratio in the 20 dogs showing hypoalbuminemia (< 2.5 g/dl) was significantly higher than that in the 9 dogs with normal serum albumin levels > 2.5 g/dl (P<0.01).In conclusion, permeability of the intestinal mucosa as determined by the urinary L:R ratio could be a useful laboratory parameter for evaluating intestinal damage in LPE dogs.

show abstract

“…For example, numerous in vivo human studies have shown that disruption of intestinal epithelial barrier function closely mirrors disease activity and actually correlates with CD45RO expression on circulating CD19 positive B cells. [9][10][11] Even more intriguing is the observation that, in clinically asymptomatic Crohn's disease patients, increased intestinal epithelial permeability precedes clinical relapse by as much as 1 year, [12][13][14] indicating that a permeability defect may be an early event in disease reactivation. Further evidence supporting the hypothesis that abnormal intestinal barrier function occurs early in the pathogenesis of Crohn's disease comes from numerous studies showing that a subset of clinically healthy first-degree relatives of Crohn's disease patients have abnormally increased intestinal permeability.…”

mentioning

confidence: 99%

A porous defense: the leaky epithelial barrier in intestinal disease

Clayburgh

Shen

Turner

2004

Laboratory Investigation

437

357

View full text Add to dashboard Cite

A critical function of the intestinal mucosa is to form a barrier that separates luminal contents from the interstitium. This intestinal barrier is compromised in a number of intestinal diseases, most notably inflammatory bowel disease. In vitro studies have demonstrated that cytokines elaborated by immune cells can cause the mucosal barrier to become leaky; these cytokines are known to be increased in intestinal mucosa involved in inflammatory bowel disease. Detailed information describing the mechanisms by which altered cytokine signaling occurs is not available, but recent data implicate the cytoskeleton within epithelial cells as a critical regulator of the mucosal barrier under physiological and pathophysiological conditions. Using available data, we describe a model of intestinal disease where an initial insult to the epithelial barrier may trigger a selfamplifying cycle of immune activation, cytokine release, and further barrier dysfunction. This model is supported by the observation that pharmacological abrogation of cytokine signaling corrects both barrier defects and clinical disease in animal models and human patients, although such therapy clearly has multiple mechanisms. Other therapeutic targets that represent strategies to prevent or reverse disease processes are also considered. The overarching hypothesis is that modulation of the mucosal epithelial barrier plays a critical role in the initiation and propogation of inflammatory intestinal diseases.

show abstract

The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease

Cited by 65 publications

References 27 publications

Assessment of intestinal permeability in preruminant calves by lactulose/mannitol test

Assessment of intestinal permeability in preruminant calves by lactulose/mannitol test

Measurement of Intestinal Mucosal Permeability in Dogs with Lymphocytic-Plasmacytic Enteritis

A porous defense: the leaky epithelial barrier in intestinal disease

Contact Info

Product

Resources

About